A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma
暂无分享,去创建一个
K. Do | E. Jonasch | K. Shaw | P. Corn | L. Doyle | A. Zurita | X. Wang | P. Lara | N. Tannir | T. Moss | E. Hasanov | S. Stovall | N. Tannir | B. Gan | V. Marcott | S. Bird | P. Altamirano | P. N. Lara | Xin A. Wang | Xin A. Wang
[1] A. Ravaud,et al. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Stephens,et al. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. , 2016, European urology.
[3] E. V. Van Allen,et al. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies , 2016, Cancer.
[4] R. Motzer,et al. A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma , 2016, The oncologist.
[5] A. Belldegrun,et al. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma , 2016, Proceedings of the National Academy of Sciences.
[6] Martin O. Leach,et al. Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers , 2014, Clinical Cancer Research.
[7] C. Porta,et al. Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..
[8] Li Ma,et al. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. , 2014, Cancer research.
[9] R. Figlin,et al. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors , 2013, International journal of cancer.
[10] Carol Prives,et al. Mutant p53: one name, many proteins. , 2012, Genes & development.
[11] R. Figlin,et al. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor‐targeted therapy , 2012, Cancer.
[12] P. Argani,et al. Immunoexpression Status and Prognostic Value of mTOR and Hypoxia-Induced Pathway Members in Primary and Metastatic Clear Cell Renal Cell Carcinomas , 2011, The American journal of surgical pathology.
[13] G. Mills,et al. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[15] P. Tamboli,et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low‐dose interferon alfa in patients with advanced renal cell carcinoma , 2009, Cancer.
[16] C. Kolbitsch,et al. Increased activated Akt expression in renal cell carcinomas and prognosis , 2009, Journal of cellular and molecular medicine.
[17] M. Kuczyk,et al. Activation of PI3K Is Associated with Reduced Survival in Renal Cell Carcinoma , 2008, Urologia Internationalis.
[18] W. Kaelin,et al. Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Toshiyuki Obata,et al. Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53* , 2002, The Journal of Biological Chemistry.
[20] P. Schirmacher,et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. , 2000, Cancer research.
[21] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[22] K. Harada,et al. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy. , 2014, Urologic oncology.